By whatever starting metric is used, the withdrawal process for Covis Pharma’s preterm birth prevention drug Makena (hydroxyprogesterone caproate) was a long one, with the drug removed from the market:
Approximately 41 months passed from the initial advisory committee meeting in October 2019 on Makena’s potential withdrawal to the 5 April 2023 final decision by FDA Commissioner Robert Califf and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?